Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 24, 2016

View Archived Issues

Allergan completes acquisition of Chase Pharmaceuticals

Viral Gene announces phase II funding for novel vaccine to prevent colon cancer metastases

Juno Therapeutics places clinical hold on phase II ROCKET trial of JCAR-015

Proteros and Merck Sharp & Dohme sign second oncology collaboration on epigenetic target

SM-04755 demonstrates promise in models of psoriasis, chronic tendinopathy and scleroderma

LPA receptor 1 as a target for diabetic nephropathy

Pfizer patents myeloperoxidase irreversible inhibitors

Genentech and Roche disclose retinoid RORgamma receptor ligands

Pfizer describes JAK inhibitors

Rayaldee set for U.S. launch

Sun Pharma signs definitive agreement to acquire JSC Biosintez

Sanofi Pasteur MSD vaccines joint venture to end next month

PRX-OTC from PhaseRx receives FDA orphan drug designation

European Commission grants conditional marketing authorization for Ninlaro

Institute of Human Virology announces grants and new international center to tackle HIV/AIDS

Navidea signs Lymphoseek asset purchase agreement with Cardinal Health

FDA grants orphan drug designation to ABTL-0812 for the treatment of pancreatic cancer

NeuroSearch outlines plan for remaining assets after Danish Supreme Court decision

Filgotinib begins phase III trial in Crohn's disease

C3c may be useful to monitor psoriatic arthritis

Arsanis initiates phase II trial of ASN-100 to prevent S. aureus pneumonia

RGC upregulation may have a pathogenic role in lupus nephritis

Xencor initiates phase I study of XmAb-13676 for CD20-expressing hematologic malignancies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...